Acobiom discovered and patented a set of blood RNA-biomarkers that are correlated to a 14.9-month survival prognosis in Pancreatic Cancer patients treated by Gemcitabine.
From this new Blood RNA-biomarker signature, Acobiom developed a new In-Vitro Diagnostic, called GemciTest, based on qRT-PCR technology.
Hence, the GemciTest can identify the patients suffered from pancreatic cancer that are the most likely to benefit from gemcitabine.
To illustrate the overall survival benefits of the GemciTest, the sub-population of patients identified by the GemciTest is characterized by the following rates:
> 65% of them are alive 12 months after the diagnostic of the disease (versus 35%* for the patients treated by the combination Abraxane+Gemcitabine and 24% for the patients treated blindly by gemcitabine),
> 50% of them are alive 14.9 months after the diagnostic of the disease (versus 20%* for the patients treated by the combination Abraxane+Gemcitabine and 11% for the patients treated blindly by gemcitabine).
The SOP of the GemciTest is available for routine analyses and the diagnostic can be ordered for « Research Use Only » (RUO).
If you need more information, please contact our business development department (T: +33(0)467 419 748, Email: email@example.com).